Effects of treatment with glucagon-like peptide-2 on bone resorption in colectomized patients with distal ileostomy or jejunostomy and short-bowel syndrome

• Published in: Scandinavian journal of gastroenterology 2008, Vol.43 (11), p.1304-1310
• Main Authors: Gottschalck, Ida B., Jeppesen, Palle B., Hartmann, Bolette, Holst, Jens J., Henriksen, Dennis B.
• Format: Article
• Language: English
• Subjects: Adult; Biological and medical sciences; Body Mass Index; Bone Density; Bone Density Conservation Agents - administration & dosage; Bone Resorption - drug therapy; Bone Resorption - etiology; Circadian Rhythm; Colectomy; Female; Gastroenterology. Liver. Pancreas. Abdomen; GLP-2; Glucagon-Like Peptide 2 - administration & dosage; Humans; Ileostomy; Injections, Subcutaneous; Jejunostomy; Male; Medical sciences; Middle Aged; Other diseases. Semiology; Parathyroid Hormone - blood; PTH; s-CTX; Short Bowel Syndrome - complications; Short Bowel Syndrome - physiopathology; short-bowel syndrome; Stomach, duodenum, intestine, rectum, anus; Stomach. Duodenum. Small intestine. Colon. Rectum. Anus; Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases; Surgery of the digestive system; Treatment Outcome
• ISSN: 0036-5521; 1502-7708
• DOI: 10.1080/00365520802200028

Objective. The gut hormone GLP-2 (glucagon-like peptide-2) seems to be involved in the circadian pattern of bone resorption, whereas parathyroid hormone (PTH) is an established key hormone in bone turnover. Endogenous GLP-2 secretion is lacking in colectomized patients with short-bowel syndrome (SBS) and they have reduced bone mineral density (BMD). The aim of the study was to investigate the anti-resorptive effect (assessed by s-CTX) of 14 days of GLP-2 treatment in these patients and to determine whether 56 days of treatment would improve BMD. PTH secretion in response to GLP-2 was also investigated in colectomized SBS patients and colectomized controls (with ileostomy). Material and methods. Eight SBS patients and 13 patients with ileostomy were treated with subcutaneous injections of 1600 µg GLP-2 at bedtime for 56 and 14 consecutive days, respectively. BMD was determined at days 1 and 56 in SBS patients. On days 1 and 14, measurements of CTX, P1NP and PTH were taken 4 h after the GLP-2 injection. Results. Patients with ileostomy showed a significant reduction in bone resorption after GLP-2 injections at days 1 and 14. In contrast, there was no change in s-CTX after 1 and 14 days in the SBS patients, and after 56 days of GLP-2 treatment there was no improvement in BMD. A significant reduction in PTH secretion in response to GLP-2 was observed only in patients with ileostomy. Conclusions. The decreased bone resorption in response to GLP-2 injections cannot be elicited in SBS patients and therefore precludes treatment of their osteopenia with GLP-2. The anti-resorptive response to GLP-2 seems to require an intact small intestine and may involve suppression of PTH secretion.